Targeted delivery of PLK1-siRNA by ScFv suppresses Her2 + breast cancer growth and metastasis

Science Translational Medicine

Volumn 4, Issue 130, 2012, Pages

  Yao, Yan Dan ^a   Sun, Tian Meng ^b   Huang, Song Yin ^a   Dou, Shuang ^b   Lin, G ^a   Chen, Jia Ning ^a   Ruan, Jian Bin ^b   Mao, Cheng Qiong ^b   Yu, Feng Yan ^a   Zeng, Mu Sheng ^c   Zang, Jian Ye ^b   Liu, Qiang ^a   Su, Feng Xi ^a   Zhang, Peter ^d   Lieberman, Judy ^e   Wang, Jun ^b   Song, Erwei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d Shanghai GenePharma Co Ltd   (China)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERFERON; POLO LIKE KINASE 1; PROTEIN F5 P; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

AKT GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CCND1 GENE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PLK1 GENE; PRIORITY JOURNAL; TOXICITY TESTING; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG SCREENING; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860211700     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003601     Document Type: Article

References (35)

1. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, W. L. McGuire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
2. K. L. Jones, A. U. Buzdar, Evolving novel anti-HER2 strategies. Lancet Oncol. 10, 1179-1187 (2009).
3. F. Eckerdt, J. Yuan, K. Strebhardt, Polo-like kinases and oncogenesis. Oncogene 24, 267-276 (2005).
4. F. A. Barr, H. H. Silljé, E. A. Nigg, Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5, 429-440 (2004).
5. Y. Degenhardt, T. Lampkin, Targeting Polo-like kinase in cancer therapy. Clin. Cancer Res. 16, 384-389 (2010).
6. R. Guan, P. Tapang, J. D. Leverson, D. Albert, V. L. Giranda, Y. Luo, Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res. 65, 2698-2704 (2005).
7. B. Spänkuch, I. Steinhauser, H. Wartlick, E. Kurunci-Csacsko, K. I. Strebhardt, K. Langer, Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 10, 223-234 (2008).
8. A. D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock, I. MacLachlan, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119, 661-673 (2009).
9. B. Spänkuch, Y. Matthess, R. Knecht, B. Zimmer, M. Kaufmann, K. Strebhardt, Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J. Natl. Cancer Inst. 96, 862-872 (2004).
10. E. Song, P. Zhu, S. K. Lee, D. Chowdhury, S. Kussman, D. M. Dykxhoorn, Y. Feng, D. Palliser, D. B. Weiner, P. Shankar, W. A. Marasco, J. Lieberman, Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
11. D. Peer, P. Zhu, C. V. Carman, J. Lieberman, M. Shimaoka, Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. U.S.A. 104, 4095-4100 (2007).
12. W. H. Wen, J. Y. Liu, W. J. Qin, J. Zhao, T. Wang, L. T. Jia, Y. L. Meng, H. Gao, C. F. Xue, B. Q. Jin, L. B. Yao, S. Y. Chen, A. G. Yang, Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 46, 84-94 (2007).
13. X. Li, P. Stuckert, I. Bosch, J. D. Marks, W. A. Marasco, Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther. 8, 555 -565 (2001).
14. R. Bartz, H. Fan, J. Zhang, N. Innocent, C. Cherrin, S. C. Beck, Y. Pei, A. Momose, V. Jadhav, D. M. Tellers, F. Meng, L. S. Crocker, L. Sepp-Lorenzino, S. F. Barnett, Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape. Biochem. J. 435, 475-487 (2011).
15. H. Y. Chen, J. Yang, C. Lin, Y. A. Yuan, Structural basis for RNA-silencing suppression by Tomato aspermy virus protein 2b. EMBO Rep. 9, 754-760 (2008).
16. E. J. Kim, T. G. Park, Y. K. Oh, C. K. Shim, Assessment of siRNA pharmacokinetics using ELISA-based quantification. J. Control. Release 143, 80-87 (2010).
17. A. Müller, B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A. Mohar, E. Verástegui, A. Zlotnik, Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
18. K. Karikó, P. Bhuyan, J. Capodici, D. Weissman, Small interfering RNAs mediate sequenceindependent gene suppression and induce immune activation by signaling through Toll-like receptor 3. J. Immunol. 172, 6545-6549 (2004).
19. S. I. Pai, Y. Y. Lin, B. Macaes, A. Meneshian, C. F. Hung, T. C. Wu, Prospects of RNA interference therapy for cancer. Gene Ther. 13, 464- 477 (2006).
20. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R. K. Pandey, T. Racie, K. G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, H. P. Vornlocher, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
21. K. Gao, L. Huang, Nonviral methods for siRNA delivery. Mol. Pharm. 6, 651-658 (2009).
22. E. Ashihara, E. Kawata, T. Maekawa, Future prospect of RNA interference for cancer therapies. Curr. Drug Targets 11, 345-360 (2010).
23. C. S. Gondi, J. S. Rao, Concepts in in vivo siRNA delivery for cancer therapy. J. Cell. Physiol. 220, 285-291 (2009).
24. L. S. Mangala, H. D. Han, G. Lopez-Berestein, A. K. Sood, Liposomal siRNA for ovarian cancer. Methods Mol. Biol. 555, 29-42 (2009).
25. Y. K. Oh, T. G. Park, siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61, 850-862 (2009).
26. F. Takeshita, T. Ochiya, Therapeutic potential of RNA interference against cancer. Cancer Sci. 97, 689-696 (2006).
27. P. N. Pushparaj, A. J. Melendez, Short interfering RNA (siRNA) as a novel therapeutic. Clin. Exp. Pharmacol. Physiol. 33, 504-510 (2006).
28. M. E. Davis, J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
29. D. T. Auguste, K. Furman, A. Wong, J. Fuller, S. P. Armes, T. J. Deming, R. Langer, Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J. Control. Release 130, 266-274 (2008).
30. A. S. Lo, Q. Zhu, W. A. Marasco, Intracellular antibodies (intrabodies) and their therapeutic potential. Handb. Exp. Pharmacol. 181, 343-373 (2008).
31. C. A. Sledz, M. Holko, M. J. de Veer, R. H. Silverman, B. R. Williams, Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839 (2003).
32. Y. Byun, L. C. Chang, L. M. Lee, I. S. Han, V. K. Singh, V. C. Yang, Low molecular weight protamine: A potent but nontoxic antagonist to heparin/low molecular weight protamine. ASAIO J. 46, 435-439 (2000).
33. S. Y. Chen, C. Zani, Y. Khouri, W. A. Marasco, Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 2, 116-123 (1995).
34. J. C. He, M. Husain, M. Sunamoto, V. D. D'Agati, M. E. Klotman, R. Iyengar, P. E. Klotman, Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J. Clin. Invest. 114, 643-651 (2004).
35. U. Steidl, C. Steidl, A. Ebralidze, B. Chapuy, H. J. Han, B. Will, F. Rosenbauer, A. Becker, K. Wagner, S. Koschmieder, S. Kobayashi, D. B. Costa, T. Schulz, K. B. O'Brien, R. G. Verhaak, R. Delwel, D. Haase, L. Trümper, J. Krauter, T. Kohwi-Shigematsu, F. Griesinger, D. G. Tenen, A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J. Clin. Invest. 117, 2611-2620 (2007).